-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Short Interest in Bionomics Limited (NASDAQ:BNOX) Rises By 150.0%
Short Interest in Bionomics Limited (NASDAQ:BNOX) Rises By 150.0%
Bionomics Limited (NASDAQ:BNOX – Get Rating) was the recipient of a large growth in short interest during the month of December. As of December 30th, there was short interest totalling 1,000 shares, a growth of 150.0% from the December 15th total of 400 shares. Based on an average trading volume of 6,300 shares, the days-to-cover ratio is currently 0.2 days.
Bionomics Stock Performance
Shares of BNOX stock traded down $0.22 during trading hours on Wednesday, reaching $4.13. 95 shares of the company's stock were exchanged, compared to its average volume of 3,657. The stock's 50 day moving average is $6.07 and its 200-day moving average is $7.02. Bionomics has a fifty-two week low of $3.51 and a fifty-two week high of $12.99.
Get Bionomics alerts:Analysts Set New Price Targets
BNOX has been the topic of a number of research reports. HC Wainwright lowered shares of Bionomics from a "buy" rating to a "neutral" rating in a research report on Monday, December 19th. Loop Capital assumed coverage on shares of Bionomics in a research note on Tuesday, November 1st. They issued a "buy" rating and a $23.00 price objective for the company. Finally, Evercore ISI restated an "in-line" rating and set a $6.00 price objective (down from $17.00) on shares of Bionomics in a research note on Tuesday, December 20th.
About Bionomics
(Get Rating)Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.
See Also
- Get a free copy of the StockNews.com research report on Bionomics (BNOX)
- J.B. Hunt Gets A Flat, Logistic Companies Come Into Focus
- Is Intel Stock On The Verge Of Breaking Out?
- Does it Matter Folks Aren't "Starry-Eyed" Over Pepsi's New Soda?
- Can Alaska Air Continue Soaring Above The Airline Industry?
- Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?
Receive News & Ratings for Bionomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionomics and related companies with MarketBeat.com's FREE daily email newsletter.
Bionomics Limited (NASDAQ:BNOX – Get Rating) was the recipient of a large growth in short interest during the month of December. As of December 30th, there was short interest totalling 1,000 shares, a growth of 150.0% from the December 15th total of 400 shares. Based on an average trading volume of 6,300 shares, the days-to-cover ratio is currently 0.2 days.
生物學有限公司(NASDAQ:BNOX-獲得評級)在十二月份期間是短期興趣大幅增長的接收者。截至 12 月 30 日,總共有 1,000 股的短期利息,較 12 月 15 日共 400 股股份增長 150.0%。根據 6,300 股的平均交易量,目前的天數比率為 0.2 天。
Bionomics Stock Performance
人體學股票表現
Shares of BNOX stock traded down $0.22 during trading hours on Wednesday, reaching $4.13. 95 shares of the company's stock were exchanged, compared to its average volume of 3,657. The stock's 50 day moving average is $6.07 and its 200-day moving average is $7.02. Bionomics has a fifty-two week low of $3.51 and a fifty-two week high of $12.99.
BNOX 股票在周三的交易時間內下跌 0.22 美元,達到 4.13 美元。該公司股票的 95 股被交換,相比其平均交易量 3,657 股。該股票的 50 日移動平均線為 6.07 美元,其 200 日移動平均線為 7.02 美元。生物學的五十二周低點為 3.51 美元,五十二周高點為 12.99 美元。
Analysts Set New Price Targets
分析師設定新的價格目標
BNOX has been the topic of a number of research reports. HC Wainwright lowered shares of Bionomics from a "buy" rating to a "neutral" rating in a research report on Monday, December 19th. Loop Capital assumed coverage on shares of Bionomics in a research note on Tuesday, November 1st. They issued a "buy" rating and a $23.00 price objective for the company. Finally, Evercore ISI restated an "in-line" rating and set a $6.00 price objective (down from $17.00) on shares of Bionomics in a research note on Tuesday, December 20th.
BNOX 一直是許多研究報告的主題。在 12 月 19 日星期一的研究報告中,HC Wainwright 將生物學的股票從「買入」評級降至「中性」評級。環資本在 11 月 1 日(星期二)的研究筆記中承擔了生物組學股份的覆蓋率。他們為該公司發布了「買入」評級和 23.00 美元的價格目標。最後,永可 ISI 在 12 月 20 日(星期二)的一份研究報告中重述了「內聯」評級,並在研究報告中設定了 6.00 美元的價格目標(從 17.00 美元下跌)。
About Bionomics
關於生物學
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.
Biomics Limited 是一家臨床階段生物製藥公司,發現並開發用於治療中樞神經系統疾病和癌症的新型候選藥物。公司的主要候選藥物包括 BNC210,一種 a7 菸鹼乙酰膽鹼受體的陰性同種異體調節劑,該藥物正處於治療社交焦慮症的 2 期臨床試驗中,以及用於治療創傷後應激障礙的 2b 期臨床試驗。
See Also
另請參閱
- Get a free copy of the StockNews.com research report on Bionomics (BNOX)
- J.B. Hunt Gets A Flat, Logistic Companies Come Into Focus
- Is Intel Stock On The Verge Of Breaking Out?
- Does it Matter Folks Aren't "Starry-Eyed" Over Pepsi's New Soda?
- Can Alaska Air Continue Soaring Above The Airline Industry?
- Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?
- 獲取有關生物學(BNOX)的研究報告的免費副本
- J.B. 亨特得到一個單位, 物流公司成為焦點
- 英特爾股票是否瀕臨爆發?
- 這是否重要的人不是「星眼」在百事可樂的新蘇打水?
- 阿拉斯加航空能否繼續飆升至航空業之上?
- 約翰遜突破:盈利可以提高股票嗎?
Receive News & Ratings for Bionomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionomics and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收生物學的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件時事通訊接收生物學和相關公司的最新新聞和分析師評級的簡要每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧